🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Qiusheng Chen

Hebei Medical University

ORCID: 0000-0002-7446-0734

Also affiliated with Merck & Co., Inc., Rahway, NJ, USA (United States), Hebei North University, Hospital of Hebei Province, Hebei General Hospital, Xingtai People's Hospital

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors”.

Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2886
N/A
0DataRank · unranked
57 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more

Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6530489
N/A
0DataRank · unranked
0 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more

Data from Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6530489.v1
N/A
0DataRank · unranked
0 citations

Karen A. Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Qiusheng Chen +3 more